Aguilar-Bernier M, et al. - During June 2006 to September 2017 at the Costa del Sol Hospital (Marbella, Spain), investigators assessed 537 tumors to report the outcomes of methyl aminolevulinate (MAL-PDT) therapy (photodynamic therapy) in subjects with Bowen's disease. They observed 88% of recurrence-free survival at one year and 71% at 5 years whereas the risk of recurrence (nearly 30%) at 5 years was also noted. They found an association of increased risk of recurrence with tumor size >300 mm², its location in the upper limbs and subject's age <70 years. Recurrence of larger lesions (≥21 mm in diameter) was noticed more as compared to the smaller ones.